Ropidoxuridine

Shuttle Pharmaceuticals initiated Phase 2 trial of Ropidoxuridine for glioblastoma, aiming to improve RT outcomes. The trial will determine optimal dosing and evaluate survival rates against historical controls, expected to complete in 18-24 months.

Shuttle Pharmaceuticals has finalized agreements with six cancer centers for its Phase 2 clinical trial of Ropidoxuridine, a radiation sensitizer for glioblastoma treatment. Patients are currently being screened for enrollment, with the trial expected to complete within 18 to 24 months.

Shuttle Pharmaceuticals has finalized agreements with six cancer centers for its Phase 2 clinical trial of Ropidoxuridine, a radiation sensitizer for glioblastoma treatment. The trial aims to determine an optimal dose and expects to complete within 18-24 months, with potential to improve cancer cure rates and patient survival.

Shuttle Pharmaceuticals expands Phase 2 trial for Ropidoxuridine, a radiation sensitizer for glioblastoma, adding two sites to total four out of six planned. Targeting IDH wild-type, methylation negative patients, the trial aims to improve outcomes for this aggressive brain cancer. The study will enroll 40 patients initially, with an additional 14 to achieve statistical significance, expected to complete in 18-24 months.